In previous large pivotal clinical trials, anti-PD-1/PD-L1 ICIs with or without chemotherapy significantly improved the survival rates of metastatic NSCLC patients when compared with conventional chemotherapy alone [13,14,15]. Here, PDCD1 is linked to non-small cell lung carcinoma.